pI: 8.9638 |
Length (AA): 1269 |
MW (Da): 149482 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
140 | 878 | 3vuo (A) | 312 | 1087 | 24.00 | 0.011 | 0.85 | 0.430948 | 1.89 |
797 | 1072 | 4u0r (A) | 163 | 498 | 24.00 | 0.031 | 0.37 | 0.227094 | 0.4 |
1141 | 1266 | 4uos (A) | 3 | 133 | 15.00 | 0.14 | 0.01 | 0.187891 | -0.39 |
876 | 909 | 1ezg (A) | 37 | 70 | 38.00 | 0.48 | 0.96 | 0.837942 | -3.43 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 8 hs, intra-erythrocytic - 16 hs. | Otto TD |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | intra-erythrocytic - 24 hs, sporozoite, early ring, early trophozoite, late ring, Ring. | Otto TD PlasmoDB Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | intra-erythrocytic - 32 hs, merozoite, late trophozoite, Oocyst, Sporozoite, Female Gametocyte. | Otto TD PlasmoDB Zanghi G Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, gametocyte, Male Gametocyte. | Otto TD PlasmoDB Lasonder E |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
PlasmoDB | Data on upregulation of P. falciparum genes in different life cycle stages, combined from several microarray experiments available in PlasmoDB |
Ortholog group members (OG5_127380)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G57940 | hypothetical protein |
Arabidopsis thaliana | AT1G10490 | hypothetical protein |
Babesia bovis | BBOV_III004380 | ATPase domain containing protein |
Brugia malayi | Bm1_49950 | Hypothetical UPF0202 protein F55A12.8 in chromosome I, putative |
Candida albicans | CaO19.8143 | similar to S. cerevisiae YNL132W |
Candida albicans | CaO19.512 | similar to S. cerevisiae YNL132W |
Caenorhabditis elegans | CELE_F55A12.8 | Protein NATH-10 |
Cryptosporidium hominis | Chro.80234 | hypothetical protein |
Cryptosporidium parvum | cgd8_2000 | KRE33p like superfamily I ATPAse fused to an acetylase |
Dictyostelium discoideum | DDB_G0268868 | hypothetical protein |
Drosophila melanogaster | Dmel_CG1994 | lethal (1) G0020 |
Escherichia coli | b2474 | elongator methionine tRNA (ac4C34) acetyltransferase |
Echinococcus granulosus | EgrG_000220800 | N acetyltransferase 10 |
Entamoeba histolytica | EHI_033750 | hypothetical protein, conserved |
Echinococcus multilocularis | EmuJ_000220800 | N acetyltransferase 10 |
Giardia lamblia | GL50803_14277 | N-acetyltransferase-like protein |
Homo sapiens | ENSG00000135372 | N-acetyltransferase 10 (GCN5-related) |
Leishmania braziliensis | LbrM.17.1410 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_171350.1 | RNA cytidine acetyltransferase |
Leishmania infantum | LinJ.17.1350 | hypothetical protein, conserved |
Leishmania major | LmjF.17.1250 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.17.1250 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_00945 | hypothetical protein |
Mus musculus | 102642785 | UPF0202 protein KRE33-like |
Mus musculus | ENSMUSG00000027185 | N-acetyltransferase 10 |
Neospora caninum | NCLIV_061670 | Predicted P-loop ATPase fused to an acetyltransferase (ISS), related |
Oryza sativa | 4351627 | Os12g0170700 |
Plasmodium berghei | PBANKA_0504900 | histone acetyltransferase, putative |
Plasmodium falciparum | PF3D7_1020700 | histone acetyltransferase, putative |
Plasmodium knowlesi | PKNH_0604900 | histone acetyltransferase, putative |
Plasmodium vivax | PVX_001895 | histone acetyltransferase, putative |
Plasmodium yoelii | PY04574 | hypothetical protein |
Saccharomyces cerevisiae | YNL132W | Kre33p |
Schistosoma japonicum | Sjp_0019200 | ko:K06957 NAT10, LOC466485; N-acetyltransferase 10, putative |
Schistosoma mansoni | Smp_144490 | n-acetyltransferase-related |
Schmidtea mediterranea | mk4.001426.02 | |
Schmidtea mediterranea | mk4.000073.06 | UPF0202 protein |
Schmidtea mediterranea | mk4.000938.02 | |
Schmidtea mediterranea | mk4.001426.00 | |
Schmidtea mediterranea | mk4.001426.03 | N-acetyltransferase 10 |
Trypanosoma brucei gambiense | Tbg972.5.3580 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.5.2530 | RNA cytidine acetyltransferase |
Trypanosoma congolense | TcIL3000_5_2450 | RNA cytidine acetyltransferase |
Trypanosoma congolense | TcIL3000_5_2490 | RNA cytidine acetyltransferase |
Trypanosoma cruzi | TcCLB.509177.30 | RNA cytidine acetyltransferase |
Trypanosoma cruzi | TcCLB.511303.90 | RNA cytidine acetyltransferase |
Toxoplasma gondii | TGME49_218610 | ATPase (DUF699) protein |
Theileria parva | TP02_0251 | hypothetical protein, conserved |
Trichomonas vaginalis | TVAG_398720 | conserved hypothetical protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.5.2530 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.5.2530 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.5.2530 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.5.2530 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
b2474 | Escherichia coli | non-essential | goodall |
CELE_F55A12.8 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_F55A12.8 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_F55A12.8 | Caenorhabditis elegans | slow growth | wormbase |
CELE_F55A12.8 | Caenorhabditis elegans | sterile | wormbase |
YNL132W | Saccharomyces cerevisiae | inviable | yeastgenome |
TGME49_218610 | Toxoplasma gondii | Probably essential | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.